The NextRNA Team
NextRNA Leadership
Dominique Verhelle, PhD, MBA
Dominique Verhelle is Co-Founder, Chief Executive Officer and Chief Scientific Officer of NextRNA.
Dominique was formerly the Senior Director, Head of Academic Innovation, CEI at Takeda, where she was responsible for initiating and developing research alliances with Academic Institutes. She played a significant role accelerating innovation by building partnerships with investigators. She also contributed to creating Coho Therapeutics, a Takeda Ventures funded Newco, and was Director on the Board of Bridge Medicines.
Before her Takeda appointment, Dominique was a Principal at Third Rock Ventures. She joined in 2015 as a Strategic Advisor to focus on drug discovery and development across the portfolio of incubated companies. She played an instrumental role in building and launching Fulcrum Therapeutics and Cedilla Therapeutics.
Dominique has more than 20 years of R&D experience, principally in oncology. She was a Director Epigenetics at Pfizer in the Oncology Research Unit. Before that, she held several positions at Celgene for over nine years. She contributed to the understanding of the mechanism of action of IMiDs. She later initiated the internal epigenetic effort, led the group, and participated in partnership / M&A initiatives.
Dominique completed her postdoctoral training in the laboratory of Dr. Christopher Glass at the University of California, San Diego focusing on transcription regulation and chromatin remodeling. She holds a Ph.D. in Life Sciences from the University of Nice-Sophia-Antipolis, France, and an MBA in Entrepreneurship from the Rady School of Management, University of California, San Diego.
JS Cleiftie, MS, MBA
JS Cleiftie is NextRNA’s Chief Business Officer and Head of Finance. He is responsible for Business & Corporate Development and Finance. He joins us with 20 years of experience in Business and Corporate Development, Venture Capital, and Drug Development in Pharma and Biotech.
Most recently, JS served as Chief Business Officer of Erytech Pharma, a NASDAQ-listed clinical-stage oncology company, where he was responsible for Business Development & Licensing, External Innovation, and New Product Planning.
Prior to that, he was associate Vice-President, Global Business Development & Licensing at Sanofi, where he led and supported numerous sell-side and buy-side transactions across multiple therapeutic areas and development stages.
Before joining Sanofi, JS was a Principal at Innoven Partners, a life sciences and technology venture capital firm, where he executed numerous equity investments in private biotech and medtech companies.
He started his career in drug development in the US as a research scientist with Aventis (now Sanofi) in immunotherapy and gene therapy for cancer.
JS earned an MS in Biological & Medical Sciences and a MS in Immunology from the University of Paris V, and received his MBA from Cornell University.
Julia A Novina, Esq.
Julia Novina is one of the founding executives who helped launch NextRNA in January 2021. In her roles of Chief Legal Officer and interim Chief Administrative Officer, she oversees all legal, financial and administrative functions of the company. Prior to NextRNA, Julia served as General Counsel in three other biotechnology startup companies (Microbial Machines, Courage Therapeutics and Raqia Therapeutics) performing many of the same duties as for NextRNA, including corporate formation, founder and seed round financing, technology licensing, contracting and general company administration. Earlier in her career, Julia was a litigator, primarily in the areas of government contracts and consumer financial services. Before pivoting to her current biotechnology focus, Julia co-owned and ran small businesses and managed commercial real estate. She earned her J.D. from the Georgetown University Law Center and graduated magna cum laude from Connecticut College.
Jason Katz, PhD
Jason joined NextRNA in 2022 as VP, Head of Drug Discovery. His drug discovery experience prior to NextRNA spans an 18-year career, including 13 years at Merck & Co. followed by 5 years at IFM Therapeutics, where he was a Sr Director of Medicinal Chemistry. Jason is a scientific leader with a strong track record of recruiting, managing, and collaborating with multidisciplinary teams. At IFM Therapeutics, Jason worked on several programs targeting the innate immune system, including the team that developed a suite of NLRP3 antagonists that were acquired by Novartis and advanced into Phase 2 clinical trials. At Merck, Jason was one of the first scientists hired at the Boston site, where he developed a passion for drug discovery, working on multidisciplinary teams, and mentoring other scientists. He and his teams discovered and advanced into clinical development molecules addressing challenging oncology and immuno-oncology targets. Jason earned his Ph.D. in synthetic organic chemistry at the University of North Carolina at Chapel Hill under the direction of Michael Crimmins and then went on to study as a NIH postdoctoral fellow at UC Irvine in the labs of Larry Overman. Jason received a B.S. in Chemistry from Union College.
Alejandra Raimondi
NextRNA Team
Founders
Carl Novina, MD, PhD
Carl D. Novina MD, PhD is an Associate Professor of Medicine at the Dana-Farber Cancer Institute & Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. His lab has made several discoveries into the fundamental biology of noncoding RNAs and their dysregulation in cancers. His lab has also developed platform technologies to discover and drug non-coding RNAs and build tools for epigenetic engineering and Boolean logic gated cell therapies. He has founded three companies to accelerate the translation of these tools to the clinic. Dr. Novina is the recipient of numerous awards and honors including the W.M. Keck Distinguished Young Scholars Award, Department of Defense Idea Award, The NCI Director’s Provocative Questions Award, the National Science Foundation Collaborative Research Project Award and the NIH Director’s Pioneer Award.
Marc Cohen
In memoriam, Co-Founder, Executive Chairman, and CEO Emeritus
Marc Cohen was a co-founder, CEO, and Executive Chairman of NextRNA Therapeutics who passed away in June 2022. Marc was a pioneer who sought out and invested in innovative ideas with the goal of bringing transformative therapies to patients. Marc believed in the untapped potential of non-coding RNAs and how our approach could revolutionize the RNA therapeutic space. Marc’s passion and vision catalyzed the launch and early success of NextRNA.
Marc believed in “doing well by doing good,” and was known for his endless energy to translate novel ideas into medicines. The numerous biotechnology companies he founded over the course of his career are a testament to his passion for using his gifts to help advance breakthrough science to treatments for patients. In addition to co-founding NextRNA Therapeutics, Marc also co-founded and/or served in leadership roles at C4 Therapeutics, Frequency Therapeutics, Acetylon Pharmaceuticals, Regenacy Pharmaceuticals, OncoPep, Mana Therapeutics, Dynamic Cell Therapies and AI Proteins. He also served as Co-founder, Chairman and Chief Executive of Bublup, Inc., co-CEO, of Cobro Ventures, Inc., and co-founder and CEO of OPNET Technologies. Marc was also a long-time supporter of Dana Farber Cancer Institute, where he co-founded the Dana Farber Innovations Research Fund.
Leon Wert-Lamas, PhD, DVM
Leon Wert Lamas is currently Senior Scientist, Platform Technology at NextRNA.
He earned his License in Veterinary Medicine at Complutense University, Madrid, Spain, including clinical training at Hannover Veterinary School (Germany), where he completed his thesis on allergies in the laboratory of Prof. Wolfgang Leibold.
After finishing Veterinary School, where he specialized in the therapeutics of parasitic diseases, Leon completed a PhD on non-coding RNA medicine in thyroid cancer in the Laboratory of Pilar Santisteban at Sols Biomedical Institute and Autonoma University Medical School, Madrid. In his thesis work, he pioneered the use of microRNA mimics and modulators as thyroid cancer therapeutics. During his PhD he did a 4-month internship at Boston Children’s Hospital in Boston in the laboratory of Richard Gregory.
Leon was awarded prizes for best communication in Genetics at the 17th Congress of the European Society of Endocrinology (2015, Dublin), the ”Best Published Work on Thyroid Disease Award“ by the Spanish Endocrinology Society (2015), and the Best Poster in Genetics and Disease Biology at the 15th Annual Retreat of the Broad Institute of Harvard and MIT (2019).
After completing his PhD, Leon accepted a Research Fellow position in the laboratory of Carl Novina, where he led the development of platform technologies that was foundational work for NextRNA. Leon is excited to continue his work identifying and drugging disease-relevant RNA-protein interactions at NextRNA.
Dominique Verhelle, PhD, MBA
Dominique Verhelle is a cofounder, who has led the scientific and corporate strategy of NextRNA since its launch in January 2021. She currently manages the scientific team, consultants, SAB, and oversees the broader business, finance, and operations of the company.
Dominique was formerly the Senior Director, Head of Academic Innovation, CEI at Takeda, where she was responsible for initiating and developing research alliances with Academic Institutes. She played a significant role accelerating innovation by building partnerships with investigators. She also contributed to creating Coho Therapeutics, a Takeda Ventures funded Newco, and was Director on the Board of Bridge Medicines.
Before her Takeda appointment, Dominique was a Principal at Third Rock Ventures. She joined in 2015 as a Strategic Advisor to focus on drug discovery and development across the portfolio of incubated companies. She played an instrumental role in building and launching Fulcrum Therapeutics and Cedilla Therapeutics.
Dominique has more than 20 years of R&D experience, principally in oncology. She was a Director Epigenetics at Pfizer in the Oncology Research Unit. Before that, she held several positions at Celgene for over nine years. She contributed to the understanding of the mechanism of action of IMiDs. She later initiated the internal epigenetic effort, led the group, and participated in partnership / M&A initiatives.
Dominique completed her postdoctoral training in the laboratory of Dr. Christopher Glass at the University of California, San Diego focusing on transcription regulation and chromatin remodeling. She holds a Ph.D. in Life Sciences from the University of Nice-Sophia-Antipolis, France, and an MBA in Entrepreneurship from the Rady School of Management, University of California, San Diego.
Kenneth Anderson, MD
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. Over the last four decades, he has developed laboratory and animal models of myeloma in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies. He has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies, which have markedly improved patient outcome. He received the American Society of Hematology William Dameshek Prize, the American Association for Cancer Research Joseph H. Burchenal Award, the American Society of Clinical Oncology David A. Karnofsky Award, and the Harvard Medical School Warren Alpert Prize. He is a member of the National Academy of Medicine, and past President of the International Myeloma Society and the American Society of Hematology.
Robert Langer, PhD
Robert Langer is one of 10 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written over 1,500 articles, which have been cited over 334,000 times; his h-index of 285 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have licensed or sublicensed to over 400 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 35 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.
Board Members
Christina Henderson
Ms. Henderson has served as a director of the Company since March of 2021. Ms. Henderson is the Head of the Family Office and General Counsel of Dubin & Company. Ms. Henderson also serves as the General Counsel of Haussmann Development, a real estate development company, and the Assistant General Counsel and Compliance Officer of Commodore Capital, a biotech fund focused on late stage private and small and mid-cap public companies. In addition, Ms. Henderson previously served as acting General Counsel of Engineers Gate, a proprietary quantitative trading company, and General Counsel of Untapped Labs (fka Jumpstart Ventures, Inc.), a tech recruiting software company. In addition to serving on the board of NextRNA, she is also a member of the board of directors of Untapped Labs and previously served as a member of the board of directors of Engineers Gate. Prior to joining Dubin & Company, Ms. Henderson was an associate in the Mergers & Acquisitions group of Davis Polk & Wardwell LLP. At Davis Polk, she represented public and private clients as well as individuals in domestic and cross-border public and private mergers and acquisitions, joint ventures, corporate restructurings and advised on corporate governance and compliance issues. Ms. Henderson earned her J.D. from Harvard Law School, where she served as Captain of the Championship Ames Moot Court Team. She graduated with honors from Harvard College. Ms. Henderson is admitted in New York.
Susan Langer
Ms. Langer has served as a director of the Company since March of 2021. Ms. Langer is Chief Business Officer at two stealth biotech companies. Previously, Susan was Founding President of Kojin Therapeutics, a Boston-based start-up focused on developing transformative medicines based on its groundbreaking approach to ferroptosis and cell state biology. Prior to joining Kojin, Susan was Head of Corporate Strategy at Biogen. During her seven years at Biogen, Susan led the strategy and execution of more than a dozen corporate transactions as well as company-wide initiatives, including expanding the neuromuscular and rare disease franchises. She also played an integral role in deal evaluation and portfolio planning for various parts of the business, including multiple sclerosis, gene therapy, dementia and neurocognition, ophthalmology and non-malignant hematology. She received a BA from Cornell University.
William McKee
Mr. McKee has served as a director of the Company since March 2022. He currently serves as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving pharmaceutical and biotechnology companies and serves as a part-time Venture Partner for Cobro Ventures, a private investment firm focused on software and biotechnology companies. Mr. McKee served as Chief Financial Officer of C4 Therapeutics, Inc., a biopharmaceutical company, from July 2020 until June 2021. Mr. McKee served as Chief Operating Officer and Chief Financial Officer of EKR Therapeutics, Inc., from July 2010 until June 2012 when EKR was sold to Cornerstone Therapeutics Inc. From January 2009 until March 2010, Mr. McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries Limited, and the successor entity to Barr Pharmaceuticals, Inc., which was acquired by Teva in December 2008. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr Pharmaceuticals, Inc. from 1996 until 2008. Prior to joining Barr, Mr. McKee served as a Director of International Operations and Vice President Finance at Absolute Entertainment, Inc. from June 1993 until December 1994. From 1990 until June 1993, Mr. McKee worked at Gramkow & Carnevale, CPAs, and from 1983 until 1990, he worked at Deloitte & Touche. Mr. McKee serves as a director and chair of the audit committee of Aileron Therapeutics, Inc., a publicly-held biopharmaceutical company, and Assertio Therapeutics, a publicly held specialty pharmaceutical company. He also serves on the board of several privately held companies in the medical and biopharmaceutical industries. Mr. McKee holds a B.S. from the University of Notre Dame.
Barry Polisky, PhD
Dr. Polisky has served as a director of the Company since March 2021. Dr. Polisky was a Full Professor of Biology at Indiana University, where his lab studied the molecular circuitry involved in control on DNA replication initiation in plasmids. As an academic, Dr. Polisky won several awards, served on NIH study sections and Chaired the Microbial Genetics and Physiology Study Section. He also chaired scientific meetings including Gordon Conferences, served on the editorial board of multiple journals, and consulted for many companies including Eli Lilly and Cetus Corporation. Dr. Polisky left academia to become Director and Vice President of Research at NeXagen in Boulder, CO. NeXstar (formerly NeXagen) was acquired by Gilead in 1998. He then joined Ribozyme Therapeutics as Vice President of Research, which became Sirna Therapeutics, focused on development of siRNA therapeutics. Sirna was acquired by Merck Research Laboratories. He then became a Research Vice-President at Merck and directed siRNA development work until he left Merck to return to biotech at Marina Biotech, as Chief Scientific Officer. At Marina, he was involved in the acquisition of Cequent Inc., which had pioneered the use of bacteria as delivery agents. He is currently the Chairman of the Scientific Advisory Board of Marina Biotech, Inc. Dr. Polisky received a Ph.D. in Molecular Biology from the University of Colorado, Boulder.
Malcolm Salter
Mr. Salter has served as a director of the Company since February 2021. Professor Salter is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. Professor Salter is author of Innovation Corrupted (Harvard University Press, 2008), which addresses the origins and legacy of Enron’s collapse; co-author of Changing Alliances (HBS Press, 1987), a comparative study of business-government-labor relations the U.S., Japanese, and German auto industries; Diversification through Acquisition (Free Press, 1979), a study of how real economic value can be created through corporate diversification; and many other articles and papers addressing, most recently, matters of corporate purpose and governance in a post-Covid world. In addition to his scholarly activities, Professor Salter served as the School’s Senior Associate Dean for External Affairs, Chair of the Advanced Management Program and the International Senior Managers Program and Chair of the of the General Management Area.Professor Salter also served as president of Mars & Co., a strategy consulting firm with offices in Greenwich (CT), London, Paris, San Francisco, Tokyo, and Shanghai. Professor Salter is a graduate of Harvard University where he received his AB, MBA, and DBA degrees.
Bobby Sandage, PhD
Dr. Sandage has served as a director of the Company since June 2022. Dr. Sandage has almost 40 years of experience in the pharmaceutical industry in drug development and senior management positions and venture capital. He currently is the Managing Director of the Paula and Rodger Riney Foundation and Lightchain Capital, LLC, and General Partner in Cultivation Capital Life Sciences Fund II, a St. Louis venture fund. Previously he was President and CEO of Coronado BioSciences, Inc. (NASDAQ: CNDO), an immunotherapy company where he took the company public in 2011. Prior to that, he was Vice President of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the Chief Scientific Officer and Executive Vice President of Research and Development, Quality and Manufacturing at Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) (successor to Interneuron Pharmaceuticals, Inc.), which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. Dr. Sandage is currently Chair of the Board of Directors of Immunophotonics, Inc., a private oncology company and director at Endevica Biotech, Inc., a private biotech company focusing on the treatment of cachexia and Geneoscopy, a private diagnostic company for detecting colorectal cancer. He was previously served as a member of the boards of Mateon (NASDAQ: MATN), a publicly traded oncology company; Arch Oncology, Inc. a private oncology company; Gentium S.r.l. (NASDAQ: GENT) a Italian biotech company; Osteologix, Inc. (NASDAQ: OLGX) a Danish biotech company; Genta Inc. (NASDAQ: GNTA) a public oncology company. Dr. Sandage is an adjunct Professor in the Department of Pharmaceutical Sciences at Southern Illinois University Edwardsville School of Pharmacy and has published over 50 scientific articles. Dr. Sandage earned a B.S. in pharmacy from the University of Arkansas College of Pharmacy and a Ph.D. in Clinical Pharmacy from Purdue University College of Pharmacy.
Dominique Verhelle, PhD, MBA
Dominique Verhelle is Co-Founder and Chief Executive Officer of NextRNA and has served as a director of the Company since February 2021. Dominique was formerly the Senior Director, Head of Academic Innovation, CEI at Takeda, where she was responsible for initiating and developing research alliances with Academic Institutes. She played a significant role accelerating innovation by building partnerships with investigators. She also contributed to creating Coho Therapeutics, a Takeda Ventures funded Newco, and was Director on the Board of Bridge Medicines. Before her Takeda appointment, Dominique was a Principal at Third Rock Ventures. She joined in 2015 as a Strategic Advisor to focus on drug discovery and development across the portfolio of incubated companies. She played an instrumental role in building and launching Fulcrum Therapeutics and Cedilla Therapeutics. Dominique has more than 20 years of R&D experience, principally in oncology. She was a Director Epigenetics at Pfizer in the Oncology Research Unit. Before that, she held several positions at Celgene for over nine years. She contributed to the understanding of the mechanism of action of IMiDs. She later initiated the internal epigenetic effort, led the group, and participated in partnership / M&A initiatives. Dominique completed her postdoctoral training in the laboratory of Dr. Christopher Glass at the University of California, San Diego focusing on transcription regulation and chromatin remodeling. She holds a Ph.D. in Life Sciences from the University of Nice-Sophia-Antipolis, France, and an MBA in Entrepreneurship from the Rady School of Management, University of California, San Diego.